Overview

Omnigene medical technologies is actively engaged in innovations promoting accurate and precise test results from low volume and difficult samples in the area of cancer testing, and neurological conditions. The tests can be used in the clinic for patient surveillance, and in research laboratories to measure multiple analytes in a low volume or highly degraded material. The methodologies are versatile and can be used in various health areas, in research models, in archival material to minimise time lapse for validation of biomarkers, in liquid biopsies (circulating tumour cells and exosomes) and in clinical trials. The company offers genetic services in the clinical sector and microbiome analysis in health and wellbeing. The company also invests in development projects aimed to enhance existing technologies and to merge technologies towards specific aims. As a contract research organisation (CRO) we leverage our optimised methodologies to support the academic community and biotech companies to measure multiple analytes (DNA, RNA and proteins) in low input and low quality material. Omnigene Medical Technologies Ltd also represents companies that offer high-end technologies for the academic research laboratories and promotes cutting edge technologies for early detection of disease and its progression.